-
Electronic (PDF)
-
Site License
-
Enterprisewide
Virobay Inc. - Product Pipeline Review - Q4 2010
GlobalData, November 2010, Pages: 27
Virobay Inc. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Virobay Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Virobay Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Virobay Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Virobay Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Virobay Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Virobay Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Virobay Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Virobay Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Virobay Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Virobay Inc. and identify potential opportunities in those areas.
List of Tables
List of Figures
Virobay Inc. Snapshot
Virobay Inc. Overview
Key Information
Key Facts
Virobay Inc. – Research and Development Overview
Key Therapeutic Areas
Virobay Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Virobay Inc. – Pipeline Products Glance
Virobay Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Virobay Inc.–Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Virobay Inc. – Drug Profiles
VBY-129
Product Description
Mechanism of Action
R&D Progress
VBY-376
Product Description
Mechanism of Action
R&D Progress
VBY-036
Product Description
Mechanism of Action
R&D Progress
VBY-285
Product Description
Mechanism of Action
R&D Progress
VBY-825
Product Description
Mechanism of Action
R&D Progress
Virobay Inc. – Pipeline Analysis
Virobay Inc. – Pipeline Products by Therapeutic Class
Virobay Inc. Pipeline Products By Target
Virobay Inc. – Pipeline Products by Route of Administration
Virobay Inc. – Pipeline Products by Molecule Type
Virobay Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Virobay Inc., Deals Summary, 2004 to 2010
Virobay Inc. Detailed Deal Summary
Venture Financing
Virobay Raises $0.3 Million In Venture Financing
ViroBay Secures $5.47 Million In First Tranche Of Series A Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
